Initial investigations on the effect of baseline TCR repertoire on melanoma patients treated with anti-CTLA-4 or anti-PD-1, showed that a high diversity in peripheral blood, was associated with good clinical outcomes. This evidence concerns the gene CTLA4 and melanoma.